Xenon Pharmaceuticals Inc

{ "date": [ "202612", "202712", "202812", "202912", "203012" ], "revenue_estimate": [ 4.29, 52.5, 260.08, 755.1, 1151.54 ], "ebit_estimate": [ -461.48, -495.69, -321.34, 125.14, 522.62 ], "ebitda_estimate": [ -479.07, -498.74, -420.61, -160.2, 326.9 ], "net_income_estimate": [ -435.49, -477.69, -316.55, 128.88, 506.77 ], "per_share_eps_estimate": [ -4.76, -5.03, -3.23, 1.19, 4.9 ], "eps_nri_estimate": [ -4.74, -4.91, -3.29, 1.13, 4.9 ], "dividend_estimate": [ null, null, null, null, null ], "book_value_per_share_estimate": [ 11.81, 6.82, 3.3, 2.01, 6.51 ], "pretax_income_estimate": [ -434.38, -482.16, -335.07, 113.53, 451.28 ], "operating_cash_flow_per_share_estimate": [ -4.74, -4.34, -3.61, -1.77, 2.92 ], "roa_estimate": [ -49.9, -52.5, -72.55, -48.5, 63.3 ], "roe_estimate": [ -62.62, -56.7, -85.65, -73.2, 81.8 ], "gross_margin_estimate": [ 100, 94.23, 93.86, 94.03, 94.05 ], "operating_cash_flow_estimate": [ -413.73, -379.37, -315.32, -154.6, 255.05 ], "pettm_estimate": [ 0, 0, 0, 58.03, 14.07 ], "long_term_growth_rate_mean": 0, "long_term_revenue_growth_rate_mean": "272.17", "future_per_share_eps_estimate_growth": null, "future_eps_nri_estimate_growth": null, "future_revenue_estimate_growth": 272.17, "future_ebit_estimate_growth": null, "future_ebitda_estimate_growth": null, "future_dividend_estimate_growth": null, "future_net_income_estimate_growth": null, "future_pretax_income_estimate_growth": null, "future_book_value_per_share_estimate_growth": -25.35, "future_roa_estimate_growth": -13.53, "future_roe_estimate_growth": -15.16, "future_gross_margin_estimate_growth": -2.46, "future_operating_cash_flow_per_share_estimate_growth": null }

{ "date": [ "202606", "202609", "202612", "202703", "202706", "202709", "202712" ], "revenue_estimate": [ 1.25, null, 3.14, null, 0.03, 0.73, 1.95 ], "ebit_estimate": [ -112.73, -116.82, -119.25, -123.95, -126.61, -129.82, -138.78 ], "ebitda_estimate": [ -117.25, -122.37, -126.87, null, null, null, null ], "net_income_estimate": [ -105.6, -110.31, -113.07, -118.4, -121.45, -124.62, -133.47 ], "per_share_eps_estimate": [ -1.14, -1.19, -1.22, -1.29, -1.33, -1.33, -1.44 ], "eps_nri_estimate": [ -1.14, -1.18, -1.21, -1.29, -1.33, -1.33, -1.44 ], "dividend_estimate": [ null, null, null, null, null, null, null ], "book_value_per_share_estimate": [ null, null, null, null, null, null, null ], "pretax_income_estimate": [ -105.55, -108.72, -110.07, -118.4, -121.45, -124.62, -133.47 ], "operating_cash_flow_per_share_estimate": [ -5.05, -1.01, 3.55, null, null, null, null ], "roa_estimate": [ null, null, null, null, null, null, null ], "roe_estimate": [ null, null, null, null, null, null, null ], "gross_margin_estimate": [ null, null, null, null, null, null, null ], "operating_cash_flow_estimate": [ -441.1, -88.22, 310.08, null, null, null, null ], "pettm_estimate": [ 0, 0, 0, 0, null, null, null ], "long_term_growth_rate_mean": 0, "long_term_revenue_growth_rate_mean": "272.17", "future_per_share_eps_estimate_growth": null, "future_eps_nri_estimate_growth": null, "future_revenue_estimate_growth": 272.17, "future_ebit_estimate_growth": null, "future_ebitda_estimate_growth": null, "future_dividend_estimate_growth": null, "future_net_income_estimate_growth": null, "future_pretax_income_estimate_growth": null, "future_book_value_per_share_estimate_growth": -25.35, "future_roa_estimate_growth": -13.53, "future_roe_estimate_growth": -15.16, "future_gross_margin_estimate_growth": -2.46, "future_operating_cash_flow_per_share_estimate_growth": null }